Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Recent & Breaking News (NDAQ:TVTX)

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 8, 2023

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 12, 2023

Travere Therapeutics Provides Corporate Update and 2023 Outlook

GlobeNewswire January 9, 2023

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2023

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 14, 2022

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 16, 2022

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

GlobeNewswire November 15, 2022

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2022

Travere Therapeutics Reports Third Quarter 2022 Financial Results

GlobeNewswire October 27, 2022

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

GlobeNewswire October 26, 2022

Travere Therapeutics to Report Third Quarter 2022 Financial Results

GlobeNewswire October 20, 2022

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

GlobeNewswire October 13, 2022

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 11, 2022

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 14, 2022

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

GlobeNewswire August 25, 2022

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

GlobeNewswire August 22, 2022

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 11, 2022

Travere Therapeutics Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Travere Therapeutics Provides Regulatory Updates on its Development Programs

GlobeNewswire August 3, 2022

Travere Therapeutics to Report Second Quarter 2022 Financial Results

GlobeNewswire July 28, 2022